Cyclerion Therapeutics, Inc.
US ˙ NasdaqCM ˙ US23255M2044

Introduction

This page provides a comprehensive analysis of the known insider trading history of Michael J Higgins. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Michael J Higgins has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CYCN / Cyclerion Therapeutics, Inc. Director 30,740
Director 28,739
US:VYGR / Voyager Therapeutics, Inc. Director 31,314
US:PULM / Pulmatrix, Inc. Director 36,833
US:GNCA / Genocea Biosciences Inc Director 15,000
US:IRWD / Ironwood Pharmaceuticals, Inc. Chief Operating Officer 100,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Michael J Higgins. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CYCN / Cyclerion Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYCN / Cyclerion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYCN / Cyclerion Therapeutics, Inc. Insider Trades
Insider Sales CYCN / Cyclerion Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYCN / Cyclerion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYCN / Cyclerion Therapeutics, Inc. Insider Trades
Insider Purchases GNCAQ / Genocea Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYCN / Cyclerion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GNCAQ / Genocea Biosciences, Inc. Insider Trades
Insider Sales GNCAQ / Genocea Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYCN / Cyclerion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GNCAQ / Genocea Biosciences, Inc. Insider Trades
Insider Purchases IRWD / Ironwood Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYCN / Cyclerion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRWD / Ironwood Pharmaceuticals, Inc. Insider Trades
Insider Sales IRWD / Ironwood Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYCN / Cyclerion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2014-12-16 IRWD Higgins Michael J 15,987 14.0100 15,987 14.0100 223,978 287 8.4614 -88,705 -39.60
2014-11-24 IRWD Higgins Michael J 70,898 13.7500 70,898 13.7500 974,848
2014-05-29 IRWD Higgins Michael J 50,000 14.5600 50,000 14.5600 728,000
2013-03-05 IRWD Higgins Michael J 50,000 15.5700 50,000 15.5700 778,500

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IRWD / Ironwood Pharmaceuticals, Inc. Insider Trades
Insider Purchases PULM / Pulmatrix, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYCN / Cyclerion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PULM / Pulmatrix, Inc. Insider Trades
Insider Sales PULM / Pulmatrix, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYCN / Cyclerion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PULM / Pulmatrix, Inc. Insider Trades
Insider Purchases VYGR / Voyager Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CYCN / Cyclerion Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYGR / Voyager Therapeutics, Inc. Insider Trades
Insider Sales VYGR / Voyager Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CYCN / Cyclerion Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VYGR / Voyager Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Michael J Higgins as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-27 2025-03-25 4 CYCN Cyclerion Therapeutics, Inc.
Common Stock
A - Award 9,090 30,740 41.99 2.75 24,998 84,535
2024-10-10 3 CAMP Camp4 Therapeutics Corp
Common Stock
28,739
2023-12-07 3 CYCN Cyclerion Therapeutics, Inc.
Common Stock
21,650
2022-07-18 2022-07-14 4 VYGR Voyager Therapeutics, Inc.
Common Stock
S - Sale X -13,891 31,314 -30.73 6.70 -93,070 209,804
2022-01-31 2022-01-27 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 36,833 36,833
2022-01-18 2022-01-13 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 161,000 161,000
2022-01-18 2022-01-13 4 VYGR Voyager Therapeutics, Inc.
Common Stock
A - Award 45,205 45,205
2021-07-02 2021-07-01 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2021-06-04 2021-06-03 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 115,000 115,000
2021-02-01 2021-01-28 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 25,000 25,000
2020-06-19 2020-06-18 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2020-06-05 2020-06-04 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2020-04-23 2020-04-21 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2020-04-23 2016-02-03 4/A PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 8,800 8,800
2020-04-06 2020-04-02 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2020-01-13 2020-01-09 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2019-07-19 2019-07-18 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 5,625 5,625
2019-06-17 2019-06-13 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2019-05-20 2019-05-16 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2018-06-25 2018-06-21 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2018-06-18 2018-06-14 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2018-06-06 2018-06-05 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 124,000 124,000
2017-06-30 2017-06-29 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2017-06-15 2017-06-13 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000 5.34 80,100 80,100
2017-03-22 2017-03-20 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 4,400 4,400
2016-06-20 2016-06-15 4 VYGR Voyager Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-06-07 2016-06-07 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 15,000 15,000
2016-02-25 2026-02-03 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 8,800 8,800
2015-06-26 2015-06-24 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 2,217 2,217
2015-06-17 2015-06-16 4 PULM Pulmatrix, Inc.
Stock Option (Right to Buy)
A - Award 35,419 35,419
2015-02-27 2015-02-26 4 GNCA GENOCEA BIOSCIENCES, INC.
Stock Option (Right to Buy)
A - Award 10,084 10,084
2014-12-24 2014-12-23 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -29,102 100,000 -22.54
2014-12-24 2014-12-23 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 29,102 329,102 9.70 1.56 45,399 513,399
2014-12-18 2014-12-16 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -15,987 34,013 -31.97
2014-12-18 2014-12-16 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale -15,987 300,000 -5.06 14.01 -223,978 4,203,000
2014-12-18 2014-12-16 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 15,987 315,987 5.33 2.94 47,002 929,002
2014-11-26 2014-11-24 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -70,898 129,102 -35.45
2014-11-26 2014-11-24 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale -70,898 300,000 -19.12 13.75 -974,848 4,125,000
2014-11-26 2014-11-24 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 70,898 370,898 23.63 1.56 110,601 578,601
2014-05-30 2014-05-29 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
S - Sale -50,000 0 -100.00 14.56 -728,000
2014-03-05 2014-03-03 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 85,000 85,000
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -33,334 0 -100.00
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -80,900 0 -100.00
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class A Common Stock
M - Exercise 50,000 50,000 0.60 30,000 30,000
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 33,334 300,000 12.50 0.60 20,000 180,000
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale X -5,900 266,666 -2.16 11.84 -69,856 3,157,325
2013-06-18 2013-06-17 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 30,900 272,566 12.79 0.60 18,540 163,540
2013-06-18 2013-06-14 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -144,100 80,900 -64.04
2013-06-18 2013-06-14 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale X -144,100 241,666 -37.35 11.74 -1,691,734 2,837,159
2013-06-18 2013-06-14 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 144,100 385,766 59.63 0.60 86,460 231,460
2013-03-07 2013-03-06 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
M - Exercise -100,000 33,334 -75.00
2013-03-07 2013-03-06 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
M - Exercise 100,000 241,666 70.59 0.60 60,000 145,000
2013-03-07 2013-03-05 4 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
S - Sale -50,000 141,666 -26.09 15.57 -778,500 2,205,740
2013-02-05 2013-02-01 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 90,000 90,000
2012-02-03 2012-02-01 4 IRWD IRONWOOD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy)
A - Award 85,000 85,000
2010-02-02 3 IRWD IRONWOOD PHARMACEUTICALS INC
Class B Common Stock
150,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)